AtriCure (ATRC) News Today

Emerald Advisers LLC reduced its stake in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 22.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 351,415 shares of the medical device company's stock

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has received a consensus rating of "Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages

StockNews.com upgraded AtriCure from a "sell" rating to a "hold" rating in a research note on Wednesday.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 3,640,000 shares, a growth of 17.0% from the July 31st total of 3,110,000 shares. Based on an average trading volume of 888,500 shares, the days-to-cover ratio is presently 4.1 days.

Panagora Asset Management Inc. lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 8.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 309,547 shares of the medical device compa

AtriCure (NASDAQ:ATRC) Stock Price Up 4.1%

StockNews.com lowered AtriCure from a "hold" rating to a "sell" rating in a report on Tuesday.

AtriCure (NASDAQ:ATRC) Trading 3.2% Higher

Assenagon Asset Management S.A. decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 79.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,084 shares of the medical device company's stock a

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Maggie Yuen sold 3,500 shares of the company's stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $24.07, for a total value of $84,245.00. Following the sale, the director now owns 8,970 shares in the company, valued at approximately $215,907.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 3,110,000 shares, a drop of 14.3% from the July 15th total of 3,630,000 shares. Based on an average trading volume of 889,800 shares, the days-to-cover ratio is presently 3.5 days.

AtriCure (NASDAQ:ATRC) Trading 8.3% Higher

Price T Rowe Associates Inc. MD lessened its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 91.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,202 shares of the medical device compa

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has received an average rating of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts th

CANADA LIFE ASSURANCE Co lessened its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 85.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,041 shares of the medical devic

BTIG Research cut their price target on AtriCure from $58.00 to $53.00 and set a "buy" rating on the stock in a research note on Wednesday.

Kennedy Capital Management LLC increased its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 115.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 227,193 shares of the medical device company's stock after b

Silvercrest Asset Management Group LLC lessened its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 26.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 190,550 shares of the medical device company's stock after selling 67,315

Bellevue Group AG trimmed its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 45.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 447,376 shares of the medical device company's stock after selling 370,507 shares during the period. Bellevue Group

AtriCure (NASDAQ:ATRC) will be releasing earnings after the market closes on Tuesday, July 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=607027)

AtriCure (NASDAQ:ATRC) Shares Up 4.4%

BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 17.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 377,822 shares of the medical device company's stoc

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month pr

TimesSquare Capital Management LLC trimmed its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 12.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 854,547 shares of the medical device company's s

Vanguard Group Inc. lifted its position in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,766,029 shares of the medical device company's stock after buying an ad

Wasatch Advisors LP increased its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 38.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 720,677 shares of the medical device company's stock after purchasing an additional

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 3,300,000 shares, a drop of 6.5% from the May 31st total of 3,530,000 shares. Based on an average daily volume of 796,200 shares, the days-to-cover ratio is currently 4.1 days.

AtriCure (NASDAQ:ATRC) Trading 4.7% Higher

Wellington Management Group LLP increased its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,329,457 shares of the medical device company'

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 12 month price objective amo